MindWalk (HYFT) versus Its Peers Head-To-Head Analysis

MindWalk (NASDAQ:HYFT) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare MindWalk to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, profitability, earnings, risk and dividends.

Profitability

This table compares MindWalk and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-105.11%	-133.26%	-77.78%
MindWalk Competitors	-538.84%	77.19%	-13.52%

Analyst Recommendations

This is a summary of recent ratings and price targets for MindWalk and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
MindWalk Competitors	957	3187	5522	178	2.50

MindWalk presently has a consensus price target of $5.00, indicating a potential upside of 410.20%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 0.60%. Given MindWalk’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MindWalk is more favorable than its rivals.

Insider and Institutional Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares MindWalk and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$16.23 million	-$10.11 million	-3.77
MindWalk Competitors	$2.33 billion	$55.11 billion	-7.39

MindWalk’s rivals have higher revenue and earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

MindWalk has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, MindWalk’s rivals have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.

Summary

MindWalk rivals beat MindWalk on 8 of the 13 factors compared.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.